These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

650 related items for PubMed ID: 16564428

  • 1. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
    Dekundy A, Pietraszek M, Schaefer D, Cenci MA, Danysz W.
    Brain Res Bull; 2006 Apr 14; 69(3):318-26. PubMed ID: 16564428
    [Abstract] [Full Text] [Related]

  • 2. mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition.
    Pietraszek M, Gravius A, Schäfer D, Weil T, Trifanova D, Danysz W.
    Neuropharmacology; 2005 Jul 14; 49(1):73-85. PubMed ID: 15992582
    [Abstract] [Full Text] [Related]

  • 3. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Johnston TH, Fox SH, McIldowie MJ, Piggott MJ, Brotchie JM.
    J Pharmacol Exp Ther; 2010 Jun 14; 333(3):865-73. PubMed ID: 20231306
    [Abstract] [Full Text] [Related]

  • 4. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F, Marti M, Dekundy A, Danysz W, Morari M, Cenci MA.
    J Neurochem; 2007 Apr 14; 101(2):483-97. PubMed ID: 17359492
    [Abstract] [Full Text] [Related]

  • 5. MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats.
    Ossowska K, Konieczny J, Wolfarth S, Pilc A.
    Neuropharmacology; 2005 Sep 14; 49(4):447-55. PubMed ID: 15919101
    [Abstract] [Full Text] [Related]

  • 6. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF, Leo G, Vergoni AV, Martínez E, Hockemeyer J, Lluis C, Franco R, Fuxe K, Ferré S.
    Brain Res Bull; 2004 Aug 30; 64(2):155-64. PubMed ID: 15342103
    [Abstract] [Full Text] [Related]

  • 7. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
    Marin C, Jiménez A, Tolosa E, Bonastre M, Bové J.
    Synapse; 2004 Feb 30; 51(2):140-50. PubMed ID: 14618681
    [Abstract] [Full Text] [Related]

  • 8. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
    Kobylecki C, Cenci MA, Crossman AR, Ravenscroft P.
    J Neurochem; 2010 Jul 30; 114(2):499-511. PubMed ID: 20456008
    [Abstract] [Full Text] [Related]

  • 9. Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats.
    Pietraszek M, Sukhanov I, Maciejak P, Szyndler J, Gravius A, Wisłowska A, Płaźnik A, Bespalov AY, Danysz W.
    Eur J Pharmacol; 2005 May 02; 514(1):25-34. PubMed ID: 15878321
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the effects of mGluR1 and mGluR5 antagonists on the expression of behavioral sensitization to the locomotor effect of morphine and the morphine withdrawal jumping in mice.
    Kotlinska J, Bochenski M.
    Eur J Pharmacol; 2007 Mar 08; 558(1-3):113-8. PubMed ID: 17222405
    [Abstract] [Full Text] [Related]

  • 11. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
    Pinna A, Tronci E, Schintu N, Simola N, Volpini R, Pontis S, Cristalli G, Morelli M.
    Neuropharmacology; 2010 Mar 08; 58(3):613-23. PubMed ID: 19951715
    [Abstract] [Full Text] [Related]

  • 12. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1998 Jun 08; 151(2):334-42. PubMed ID: 9628768
    [Abstract] [Full Text] [Related]

  • 13. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
    Mela F, Millan MJ, Brocco M, Morari M.
    Neuropharmacology; 2010 Feb 08; 58(2):528-36. PubMed ID: 19733554
    [Abstract] [Full Text] [Related]

  • 14. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.
    Brain; 2008 Dec 08; 131(Pt 12):3380-94. PubMed ID: 18952677
    [Abstract] [Full Text] [Related]

  • 15. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
    Srinivasan J, Schmidt WJ.
    Behav Brain Res; 2004 May 05; 151(1-2):191-9. PubMed ID: 15084435
    [Abstract] [Full Text] [Related]

  • 16. L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Mo J, Zhang H, Yu LP, Sun PH, Jin GZ, Zhen X.
    Neurobiol Aging; 2010 Jun 05; 31(6):926-36. PubMed ID: 18707801
    [Abstract] [Full Text] [Related]

  • 17. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Zhang H, Ma L, Wang F, Chen J, Zhen X.
    Neuropharmacology; 2007 Jul 05; 53(1):125-33. PubMed ID: 17553535
    [Abstract] [Full Text] [Related]

  • 18. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling.
    Rylander D, Recchia A, Mela F, Dekundy A, Danysz W, Cenci MA.
    J Pharmacol Exp Ther; 2009 Jul 05; 330(1):227-35. PubMed ID: 19357321
    [Abstract] [Full Text] [Related]

  • 19. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
    Lane EL, Cheetham SC, Jenner P.
    Exp Neurol; 2006 Feb 05; 197(2):284-90. PubMed ID: 16005456
    [Abstract] [Full Text] [Related]

  • 20. mGlu1 and mGlu5 receptor antagonists lack anticonvulsant efficacy in rodent models of difficult-to-treat partial epilepsy.
    Löscher W, Dekundy A, Nagel J, Danysz W, Parsons CG, Potschka H.
    Neuropharmacology; 2006 Jun 05; 50(8):1006-15. PubMed ID: 16563443
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.